Skip to main content

Gene Therapy for Treatment of Duchenne Muscular Dystrophy: Race to Bring Therapy to Market (Sarepta, Pfizer & Solid Biosciences)

Duchenne muscular dystrophy (DMD) is a rare, X-linked, fatal, degenerative neuromuscular disease caused by dystrophin gene (DMD) mutations. The Estimated incidence of DMD worldwide is 1 in 5000 live male births. 

The DMD gene encodes for the cytoskeletal protein dystrophin. Dystrophin is a 427-kDa cytoskeletal protein required for sarcolemmal stability. The deficiency of the protein leads to susceptibility to repeated cycles of necrosis and regeneration as well as diminished regenerative muscle capacity, resulting in muscle fibrosis. DMD is a progressive disorder with the loss of ambulation between age 9 and 14 years, followed by respiratory complications and cardiac function decline, and ultimately death.

Gene Therapy for DMD
The dystrophin is one of the large proteins, and the packaging of cDNA that encodes the full protein into the AAV vector (size limit- 4,500 to 5000 bp) is not possible. Evidence suggests that the truncated dystrophin are partially functional, and maybe efficacious in DMD subjects by partially rescuing the disease pathology (Becker Muscular Dystrophy like phenotype). The patients with Becker Muscular Dystrophy have partial loss of muscle function but able to work and live longer without cardiac or respiratory complications. 





Gene Therapies in Pre-clinical Stage


Labels:

Comments

Post a Comment

Popular posts from this blog

MCQs on Neisseria gonorrhoeae and Neisseria meningitidis: Medical microbiology

                                                       Multiple Choice Questions on Neisseria species (Gram-negative cocci) 1) A 19-year-old female college freshman, presented to the university health center with a severe headache, fever, and a stiff neck. She lived in a dormitory and was active in various social activities. She had received all her childhood vaccinations but had not received a booster for the meningococcal vaccine recommended before college entry. Clinical Presentation: On day 1, the patient experienced a sudden onset of fever (39.5°C or 103.1°F), severe headache, nausea, and vomiting. She also noticed a rash on her trunk and legs. Over the next two days, her symptoms deteriorated further, leading to photophobia and altered mental status. Concerned, her roommates brought her to the university health center. Physical Examinati...
4 comments
Read More

Carbohydrate Metabolism: MCQs and answers on Glycolysis & Gluconeogenesis

                                      MCQ on Glycolysis & Gluconeogenesis 1) Which of the following enzyme is not involved in galactose metabolism? a) Glucokinase b) Galactokinase c) Galactose-1-Phosphate Uridyl transferase d) UDP-Galactose 4- epimerase 2) Which of the following enzyme is defective in galactosemia (type I) - a fatal genetic disorder in infants? a) Glucokinase b) Galactokinase c) Galactose-1-Phosphate Uridyl transferase d) UDP-Galactose 4- epimerase 3) In the liver, the accumulation of which of the following metabolite attenuates the inhibitory of ATP on phosphofructokinase? a) Glucose-6-Phosphate b) Citrate c) Fructose-1,6-Bisphosphate d) Fructose-2,6-Bisphosphate 4) Mutation in which of the following enzymes leads to a glycogen storage disease known as "Tarui’s disease"? a) Glucokinase b) Phosphofructokinase c) Phosphoglucomutase d) Pyruvate Kinase 5) E...
Read More

Multiple Choice Questions (MCQs) on Diabetes Mellitus: Pathogenesis, Diagnosis and Treatment

                                        MCQs on Diabetes mellitus 1) Diabetes mellitus is a disorder characterized by hyperglycemia.  Which of the following is not the common characteristic features of type 2 diabetes mellitus ? a) Impaired insulin secretion b) Increased Insulin resistance  c) Diabetic ketoacidosis d) Excessive hepatic glucose production 2) Which of the following are the characteristic features of type 1 diabetes mellitus? a) Type 1 diabetes is caused by an absolute deficiency of insulin. b) Type 1 diabetes is associated with the autoimmune destruction of beta cells.  c) Patients with  uncontrolled type 1 diabetes present with diabetic ketoacidosis d) All of the above   3) Which of the following serum measurements are not used for the diagnosis of diabetes mellitus? a) Fasting blood glucose d) Postprandial blood glucose  c) Insulin ...
6 comments
Read More